

Study Basics

Disease: Multiple Sclerosis

Phase: 2

Global study

Total number of sites: 50

Background

In November 2020, a large, global pharmaceutical company partnered with Inato to select sites for a phase 2 Multiple Sclerosis study that will run through early 2022.



The Problem

When thinking about recruiting sites for this trial, the company was highly concerned with internal competition. They had recently launched multiple studies targeting the same disease and patient populations. Although the sponsor had established a network of partner sites, they feared that the internal competition for the same pool of patients would cannibalize the success of this study. They wanted to be able to pinpoint sites that were a good match for the trial, but not currently being used by the rest of their portfolio.

The company wanted to conduct the study globally in multiple countries but was concerned that France - a key geography for them - would not have sufficient sites to participate in the study.

"The trial application is very thorough. I liked having access to details on site motivation and experience





The Solution

By partnering with Inato, the company was able to open applications to a broad range of experienced MS sites to find exactly what they were looking for - low competition, diversity, and fast start-up times.

66%

OF ITS US-BASED
SITES EARNED
INATO'S DIVERSITY

BADGE



US STUDY TEAM MEMBER

DIVERSITY BADGE

They also discovered there were multiple sites in France that they had not previously worked with and that had the right capabilities and patient pool, ultimately leading France to be included in the global study.

The Study Team Went on to Select





...from Inato's Marketplace.

Reach out today to see how Inato can help diversify your site selection.